Genentech starts phase 2 trial to optimize delivery of eye disease cell therapy
Fierce Pharma
NOVEMBER 28, 2022
Genentech starts phase 2 trial to optimize delivery of eye disease cell therapy. ntaylor. Mon, 11/28/2022 - 10:11.
Sat.Nov 26, 2022 - Fri.Dec 02, 2022
293 
How “Lung Intelligence” is Accelerating New Therapies
MedCity News
DECEMBER 1, 2022
Thanks to the convergence of cloud technologies, AI, and refined lung data, we are in a new era for those with chronic lung disease. In this new world, lung intelligence provides fast, precision measures of treatment efficacy so new drugs can blaze through the trial pipeline.
Join 8,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
NHS expedites rollout of Bayer’s darolutamide for prostate cancer
Pharmaceutical Technology
NOVEMBER 29, 2022
The National Health Service (NHS) in England, UK, has expedited the rollout of Bayer ’s new life-extending drug, darolutamide, to treat the most advanced kinds of prostate cancer that have spread to other body parts. With the latest development, NHS will become the first healthcare system in Europe to offer this drug to prostate cancer patients. Nearly 9,000 men with prostate cancer will be eligible to receive this treatment.
First adaptive clinical trial for flu
European Pharmaceutical Review
NOVEMBER 29, 2022
A £2.9 million, UK-wide adaptive platform trial (APT) has been launched to find effective treatments for people hospitalised with severe flu for the first time, testing multiple options simultaneously in thousands of people then modifying treatments quickly. The research aims to find treatments that reduce deaths from flu and prevent patients needing intensive care.
AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Eli Lilly dumps Innovent's PD-1 after FDA rebuff, nixing high-profile Chinese cancer drug
Fierce Pharma
DECEMBER 1, 2022
Eli Lilly dumps Innovent's PD-1 after FDA rebuff, nixing high-profile Chinese cancer drug. aliu. Thu, 12/01/2022 - 15:03.
DTC Metabolic Tracker Company To Expand Personalized Nutrition Guidance With $62M
MedCity News
DECEMBER 2, 2022
Lumen sells a handheld device that measures users’ metabolism through breath and connects to an app that helps track goals and provides nutrition coaching. The funding round was led by Pitango Venture Capital, and included participation from Hanwha Group and Resolute Ventures.
Sign up to get articles personalized to your interests!
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
More Trending
AstraZeneca enters $320m deal to acquire Neogene
Pharmaceutical Technology
NOVEMBER 29, 2022
AstraZeneca has signed an agreement for the acquisition of all outstanding equity of clinical-stage biotechnology firm Neogene Therapeutics in a deal totalling up to $320m. Neogene focuses on discovering, developing and producing next-generation T-cell receptor therapies (TCR-Ts) that provide a new cell therapy approach for fighting cancer. TCR-Ts can detect intracellular targets such as cancer-specific mutations to unlock targets which were not accessible earlier using cell therapies.
With buyout on Horizon, Amgen and Sanofi eye cash plays for rare disease drug maker
Fierce Pharma
DECEMBER 2, 2022
With buyout on Horizon, Amgen and Sanofi eye cash plays for rare disease drug maker. fkansteiner. Fri, 12/02/2022 - 09:51.
How Patient Care Is Being Improved by Technology Everyday
MedCity News
DECEMBER 2, 2022
From streamlining long-held manual processes to creating entirely new diagnostic devices, new tech is cropping up all over the medtech industry—resulting in a real-world impact on patients’ quality of life.
Pfizer’s €1.2 billion manufacturing site expansion
European Pharmaceutical Review
DECEMBER 2, 2022
Pfizer Inc. has announced it will invest over €1.2 billion in its manufacturing site in Grange Castle , Dublin, the company’s biggest expansion investment to date in Ireland. A new facility will be built on the site premises, doubling the capacity for biologics manufacturing at the facility. It is anticipated a further 400-500 roles will be created, bringing the total Pfizer employees in Ireland to around 5,500.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Expanding ketamine’s horizons to treat rare neurological disorders
Pharmaceutical Technology
NOVEMBER 29, 2022
For several decades, researchers have been investigating the role of ketamine in treating depression. Now, efforts are underway to study ketamine’s effects in Parkinson’s disease, fibromyalgia, and Rett syndrome. On November 14, the Canadian developer PharmaTher announced positive data from a Phase I/II study where ketamine was used to treat levodopa-induced dyskinesia in Parkinson’s disease.
UK regulators warn of ocular side effects after treatment with Sanofi's Dupixent
Fierce Pharma
NOVEMBER 30, 2022
UK regulators warn of ocular side effects after treatment with Sanofi's Dupixent. zbecker. Wed, 11/30/2022 - 10:55.
What Should Health Systems’ Patient Access Strategies Be Heading into 2023?
MedCity News
DECEMBER 2, 2022
Health system leaders believe that improving patient access should be their top priority when strategically planning for 2023, according to a new report from the KLAS Research and UPMC’s Center for Connected Medicine. To improve patient access, respondents agreed that their health systems will need to make changes in three key areas — people, process and technology.
Company profile: NeoImmuneTech
pharmaphorum
NOVEMBER 29, 2022
NeoImmuneTech, Inc. CEO: Dr Se Hwan Yang, PhD. Headquarters: Rockville, MD, USA (2400 Research Blvd., Suite 250, Rockville, MD 20850). Locations: 3 (US HQ, Korea office, Korea R&D center). Number of employees: 90+ (as of Oct. 31, 2022). Main asset: NT-I7 (efineptakin alfa), a long-acting human IL-7. Number of on-going clinical trials: 14. Creation: Jan. 29, 2014.
US FDA approves Ferring’s Rebyota for Clostridioides difficile infection
Pharmaceutical Technology
DECEMBER 1, 2022
The US Food and Drug Administration (FDA) has granted approval for Ferring Pharmaceuticals’ faecal microbiota product, Rebyota, to prevent Clostridioides difficile infection (CDI) recurrence in people aged 18 years and above. A live biotherapeutic, Rebyota is intended for usage following the completion of antibiotic treatment. Rebyota’s safety and efficacy were analysed in the largest trial programme in the microbiome-based therapeutics field, including five trials enrolling over 1,000 subjects.
With FDA nod for its fecal microbiome therapy, Ferring becomes No. 1 in No. 2
Fierce Pharma
DECEMBER 1, 2022
With FDA nod for its fecal microbiome therapy, Ferring becomes No. 1 in No. 2. kdunleavy. Thu, 12/01/2022 - 10:14.
AHIP: Americans Want Congress To Make Telehealth Capabilities Permanent
MedCity News
DECEMBER 1, 2022
An AHIP survey found that 73% of commercially-insured telehealth users think that Congress should make telehealth provisions permanent. These provisions were put in place to meet Americans’ needs during Covid-19.
Steps to building a more patient-centric industry
pharmaphorum
DECEMBER 1, 2022
Lack of access, strict regulations, and demanding schedules have made it extremely difficult for patients to participate in clinical trials. A 2018 NIH survey found that patients felt clinical trial participation to be inconvenient and burdensome, and nearly half (49.0%) said it disrupted their daily routine. In 2021, a CISCRIP Perceptions and Insights Study reported more disruption to daily routines compared to previous years, citing length of visits, travel, and diagnostic tests as top burdens
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
C4XD and AstraZeneca enter $402m deal to develop respiratory disease therapy
Pharmaceutical Technology
NOVEMBER 28, 2022
C4X Discovery (C4XD) and AstraZeneca have entered an exclusive global licensing agreement worth up to $402m to develop oral therapy to treat inflammatory and respiratory ailments. The deal has been signed to develop the C4X NRF2 Activator programme for these ailments. Under the agreement, AstraZeneca will be responsible for the development and marketing of oral therapy for inflammatory and respiratory diseases with a key focus on chronic obstructive pulmonary disease (COPD).
Roche, having shared data with regulators, unwraps results of subcutaneous Tecentriq phase 3 trial
Fierce Pharma
DECEMBER 1, 2022
Roche, having shared data with regulators, unwraps results of subcutaneous Tecentriq phase 3 trial. ntaylor. Thu, 12/01/2022 - 09:45.
A multifaceted approach to improve cancer treatment and care
MedCity News
NOVEMBER 29, 2022
We now see the next wave of potential cancer therapies on the horizon, propelled by significant advancements in immunology, as well as an increased understanding of tumor-driven mechanisms of immune evasion.
How automation can help to address supply chain challenges in pharma
pharmaphorum
NOVEMBER 27, 2022
Supply chain issues have been rife in pharmaceuticals for a while, but current socio-economic challenges such as the conflict in Ukraine and the COVID-19 pandemic have led to extended wait times and higher prices for thousands of products. Incidents such as the hormone replacement therapy drug shortage in early 2022 have shown the damaging impact supply chain issues can have on people who depend on these drugs.
How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Diabetes Management Tech for Type II patients: Interview with Jeffrey Brewer, CEO of Bigfoot Biomedical
Medgadget
DECEMBER 1, 2022
Bigfoot Biomedical , a medtech company based in California, has developed the Bigfoot Unity System, a diabetes management technology for patients on multiple daily injection therapy. The system uses continuous glucose monitoring data and doctor recommendations to provide insulin dose recommendations, helping patients to avoid uncertainty. The company argues that type 2 diabetes patients have been historically underserved by the medtech industry, in part because such patients typically tend to be
UPDATED: GSK, with new trial win, looks to expand PD-1 Jemperli in endometrial cancer
Fierce Pharma
DECEMBER 2, 2022
UPDATED: GSK, with new trial win, looks to expand PD-1 Jemperli in endometrial cancer. zbecker. Fri, 12/02/2022 - 11:22.
A Dose of Innovation
MedCity News
NOVEMBER 29, 2022
As gene sequencing, machine learning, powerful imaging, sensors, gene and cell therapies make their way out of academic labs into everyday healthcare, our approach to healthcare is changing. For the first time, not only can we pinpoint the molecular and genetic causes of disease, but we also have the technologies to access them. On the back of this, prevention and cures are becoming possible.
Introduction to Pharmaceutical QMM Model: QMM Assessment to Promote Pharmaceutical Operational Excellence
PharmaTech
DECEMBER 2, 2022
QMM is an evolutionary advancement in FDA’s quality management maturity initiative that provides industry with a viable methodology to assess and improve manufacturing quality and supply chain reliability.
How to Stay Competitive in the Evolving State of Martech
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
Vaccines Europe launches first pipeline review
European Pharmaceutical Review
DECEMBER 2, 2022
Vaccines Europe has unveiled its first pipeline review of its 15 members companies, with 100 vaccine candidates as of July 2022. . The review revealed a pipeline aimed at tackling current and future challenges, such as antimicrobial resistance (AMR) and respiratory tract infections, through leveraging a wide range of new technology platforms. The data indicated 46 percent of the vaccine candidates target infections that do not have an available vaccine.
Roche pulls another FDA accelerated approval for cancer drug Tecentriq
Fierce Pharma
NOVEMBER 29, 2022
Roche pulls another FDA accelerated approval for cancer drug Tecentriq. kdunleavy. Tue, 11/29/2022 - 10:22.
Nvidia Aims to Simplify AI Adoption Process for Cincinnati Children’s, UCSF
MedCity News
NOVEMBER 29, 2022
Nvidia unveiled new tools designed to make it easier for hospitals to integrate AI models related to medical imaging into their clinical workflows. The tools have been adopted by major cloud infrastructure providers, as well as healthcare providers and AI software companies. Some of these include Cincinnati Children’s Hospital, University of California San Francisco, England’s National Health Service and Qure.ai.
The Top 10 Clinical Research Companies in the USA
Medico Reach
DECEMBER 2, 2022
To bring effective medicines and Innovations in healthcare industry , a Clinical Research Organization or Contract Research Organization (CRO) are a must for the Biotech, Medtech, and pharma industries. A CRO offers comprehensive support to their efforts to test, examine, refine and market the latest medicines and devices that help in improving Healthcare Industry.
Let's personalize your content